Related Story
Read the related Cover Story, "Emerging Therapies Face Development Hurdles," in the May 1, 2022 issue of BioPharm International.
Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.
In the midst of new emerging therapy projects under development, the progress of innovative manufacturing technologies is also growing. One of the newest emerging platforms for biologics manufacturing is the plant made pharmaceutical platform (PMP). PMP has come on-stage recently with the approval of Canada-based Medicago’s COVID-19 vaccine in Canada, COVIFENZ (plant-based virus-like particles, recombinant, adjuvanted) (1).
Read the related Cover Story, "Emerging Therapies Face Development Hurdles," in the May 1, 2022 issue of BioPharm International.
The wave of acceptance that has arisen with other platforms, such as baculovirus and messenger RNA, adds to the dominant mammalian cell systems. Plant-made pharmaceuticals will likely be added to the mix, according to Barry Holtz, chief scientific officer, Phylloceuticals.
Current PMP platforms use traditional soil-based or hydroponic plant growth, both of which have difficult technical challenges. Soil-based systems, for example, are largely single-level systems that require large amounts of controlled space, are dependent on specialized substrates, have inefficient materials flow, and are not as efficient to automate as vertical farming approaches. Traditional hydroponic systems require multiple movements of high-volume, heavy platforms of plants to multiple environmental zones, says Holtz.
Newer highly automated aeroponic plant growth systems can lower the costof plant-made therapeutic proteins even further, with single growth rooms systems and advance robotics.
“Plant-based manufacturing has hit the mainstream,” says Holtz. “Phylloceuticals has developed the next-generation of plant-made manufacturing [that employs] machine learning and artificial intelligence to optimize product production—an entirely different bioenergetics to product production scenario than what has traditionally been a focus on maximizing plant biomass production.”
In addition, Holtz notes that prior limitations to one product using traditional biomanufacturing are overcome in platforms such as PMP by the ability of the technology to simultaneously produce multiple products in one plant “bioreactor”.
1. Medicago, “Medicago and GSK Announce the Approval by Health Canada of COVIFENZ, an Adjuvanted Plant-Based COVID-19 Vaccine,” Press Release, Feb. 24, 2022.
About the author
Feliza Mirasol is the science editor for BioPharm International.
Article Details
BioPharm International
Vol. 35, No. 5
May 2022
Page: 12
When referring to this article, please cite it as F. Mirasol, “Emerging Plant-based Platform for Biomanufacturing,” BioPharm International 35 (5) 12 (2022).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.